Skip to content
PaperFren

cancer-immunotherapy

How does cisplatin boost checkpoint therapy?

Zhou Z, Zhao Y, Chen S, et al. · Frontiers in pharmacology · 2022

Open access · cc by · source: Europe PMC

Cisplatin-triggered tumor ferroptosis polarized N1 neutrophils and remodeled cold NSCLC tumors toward hotter T-cell/Th1 states, synergizing with ferroptosis activators in EGFR-mutant settings.

Key findings

Cisplatin induced tumor-cell ferroptosis then N1 neutrophil polarization that helped convert “cold” to “hot” tumors via T-cell infiltration and Th1 differentiation; ferroptosis activation synergized with chemoimmunotherapy in EGFR-mutant NSCLC models.

Methodology

Studied cisplatin effects on ferroptosis and neutrophil polarization in NSCLC models (including A549/LLC systems), assessed T-cell infiltration/Th1 differentiation, and tested ferroptosis-activator combinations aimed at EGFR-mutant immunotherapy resistance.

Limitations

Mouse/cell mechanisms may not fully predict human EGFR-mutant responses; clinical dosing/schedule optimization was not a randomized patient trial here.

How this study connects

Role on claims

Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.

  • SupportsFerroptosisconcept

    Triggering tumor ferroptosis can help checkpoint therapy in cold tumors (preclinical).

    In EGFR-mutant NSCLC models, cisplatin-driven tumor ferroptosis polarized N1 neutrophils and supported T-cell/Th1 programs that synergized with immune checkpoint inhibitor therapy.

    Evidence for the claim as stated.

  • SupportsFerroptosisconcept

    Cisplatin-induced ferroptosis aided ICI efficacy in cold tumors vs IRE1/JNK blockade reduced ferroptosis-linked kidney I/R injury

    Evidence for the claim as stated.

Open questions

Tensions this paper is part of

From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.

  • Scope difference — different assays, populations, or outcomes

    SupportsFerroptosis

    Cisplatin-induced ferroptosis aided ICI efficacy in cold tumors vs IRE1/JNK blockade reduced ferroptosis-linked kidney I/R injury

    Also on this tension

Related papers in this topic

Same topic cluster — not a recommendation engine.